keyword
MENU ▼
Read by QxMD icon Read
search

rocket-af

keyword
https://www.readbyqxmd.com/read/27900868/-rivaroxaban-use-in-prevention-of-stroke-in-patients-with-non-valvular-atrial-fibrillation-in-clinical-practice-results-of-observational-studies-and-our-experience
#1
Filip Málek
Rivaroxaban is direct oral factor Xa inhibitor indicated for tromboembolic event rate reduction in patients with non-valvular atrial fibrillation. Knowledge of rivaroxaban efficacy and safety comes from a phase III randomized clinical trial ROCKET AF. In the present, we have more evidence of rivaroxaban efficacy from real-life clinical studies. XANTUS study was first international prospective observational real-life study documenting use of rivaroxaban in stroke prevention in a broad population of patients with non-valvular atrial fibrillation...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27870603/indirect-comparison-of-novel-oral-anticoagulants-in-women-with-nonvalvular-atrial-fibrillation
#2
Alex Moseley, Rami Doukky, Kim Allan Williams, Amir K Jaffer, Annabelle Santos Volgman
BACKGROUND: For nonvalvular atrial fibrillation (NVAF), novel oral anticoagulants (NOACs) have been found noninferior to warfarin for stroke/systemic embolization prevention, and major bleeding events. Recent meta-analysis of NOACs versus warfarin in atrial fibrillation (AF) showed that women on warfarin have greater risk of stroke/embolism than men, and when both are treated with NOACs, differences disappear. METHODS: NOACs differ in pharmacologic properties, thus they may differ from one another in their effects on women with AF...
November 21, 2016: Journal of Women's Health
https://www.readbyqxmd.com/read/27771008/cost-effectiveness-of-non-vitamin-k-antagonist-oral-anticoagulants-for-stroke-prevention-in-patients-with-atrial-fibrillation-at-high-risk-of-bleeding-and-normal-kidney-function
#3
Inmaculada Hernandez, Kenneth J Smith, Yuting Zhang
INTRODUCTION: The comparative cost-effectiveness of all oral anticoagulants approved up to date has not been evaluated from the US perspective. The objective of this study was to compare the cost-effectiveness of edoxaban 60mg, apixaban 5mg, dabigatran 150mg, dabigatran 110mg, rivaroxaban 20mg and warfarin in stroke prevention in atrial fibrillation patients at high-risk of bleeding (defined as HAS-BLED score≥3). MATERIALS AND METHODS: We constructed a Markov state-transition model to evaluate lifetime costs and quality-adjusted life years (QALYs) with each of the six treatments from the perspective of US third-party payers...
October 15, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27751896/non-vitamin-k-antagonist-oral-anticoagulants-for-cardioversion-in-atrial-fibrillation-an-updated-meta-analysis
#4
Giulia Renda, Fabrizio Ricci, Raffaele De Caterina
BACKGROUND: Non-vitamin K oral anticoagulants are now proven alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation. However, there are few data on the efficacy and safety of their use for cardioversion, in which the risk of thromboembolic events is heightened. METHODS: We performed a random-effects meta-analysis of patients undergoing both electrical and pharmacologic cardioversion for atrial fibrillation in the RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48, X-VeRT, and ENSURE-AF trials...
October 15, 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27693993/the-c-of-chads-historical-perspective-and-clinical-applications-for-anticoagulation-in-patients-with-non-valvular-atrial-fibrillation-and-congestive-heart-failure
#5
Y Chugh, R T Faillace
The risk stratification of patients with coexisting non valvular atrial fibrillation and congestive heart failure, is often a clinical challenge, as the definitions of congestive heart failure in the popular CHADS2 and CHA2DS2VASc scoring systems, and amongst major clinical trials on Warfarin and Novel Oral Anticoagulants (NOAC) have heterogeneity. Available evidence reveals that any heart failure and/or left ventricular systolic dysfunction is associated with higher rates of stroke/systemic embolism and bleeding in patients with non valvular atrial fibrillation compared to patients without heart failure and normal left ventricular function...
December 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27624737/safety-of-non-vitamin-k-antagonist-oral-anticoagulants-in-clinical-practice-focus-on-rivaroxaban-in-stroke-prevention-in-patients-with-atrial-fibrillation
#6
Marcelo Sanmartín-Fernández, Domingo Marzal-Martín
Despite direct oral anticoagulants (DOACs) have overcome the most relevant limitations of vitamin K antagonists, many patients with atrial fibrillation are not receiving the appropriate anticoagulant therapy. In addition, when patients are anticoagulated with DOACs, some of them are not taking the dose recommended in the summary of product characteristics. This may be related, at least in part, to the concern about the applicability of findings from randomized clinical trials to real-life patients. In this context, performing studies in daily clinical practice to assess the efficacy and safety of DOACs in real-world setting is mandatory...
September 13, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27614026/standard-versus-low-dose-non-vitamin-k-antagonist-oral-anticoagulants-in-asian-patients-with-atrial-fibrillation-a-meta-analysis-of-contemporary-randomized-controlled-trials
#7
Kang-Ling Wang, Robert Giugliano, Shinya Goto, Chun-Chih Chiu, Chun-Yi Lin, En-Yu Lai, Chern-En Chiang
BACKGROUND: Although randomized controlled trials (RCTs) indicated that standard dose non-vitamin K antagonist oral anticoagulants (NOACs) were more compelling, low-dose NOACs are commonly used in clinical practice in Asia. OBJECTIVE: The purpose of this study was to assess the relative therapeutic benefits and risks of standard vs low-dose NOACs in Asian patients enrolled in contemporary RCTs. METHODS: We performed a prespecified meta-analysis of 3155 Asian patients with NOACs in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) and ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trials...
September 8, 2016: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/27595682/use-of-concomitant-aspirin-in-patients-with-atrial-fibrillation-findings-from-the-rocket-af-trial
#8
Rohan Shah, Anne Hellkamp, Yuliya Lokhnygina, Richard C Becker, Scott D Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Keith A A Fox, Christopher C Nessel, Kenneth W Mahaffey, Jonathan P Piccini, Daniel E Singer, Manesh R Patel
BACKGROUND: We aimed to investigate the relationship between aspirin use and clinical outcomes in patients enrolled in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), in particular, those with known coronary artery disease (CAD). METHODS: Patients in ROCKET AF, comparing rivaroxaban and warfarin, were analyzed. Aspirin use was assessed at baseline...
September 2016: American Heart Journal
https://www.readbyqxmd.com/read/27581874/cost-effectiveness-analysis-of-left-atrial-appendage-occlusion-compared-with-pharmacological-strategies-for-stroke-prevention-in-atrial-fibrillation
#9
Vivian Wing-Yan Lee, Ronald Bing-Ching Tsai, Ines Hang-Iao Chow, Bryan Ping-Yen Yan, Mehmet Gungor Kaya, Jai-Wun Park, Yat-Yin Lam
BACKGROUND: Transcatheter left atrial appendage occlusion (LAAO) is a promising therapy for stroke prophylaxis in non-valvular atrial fibrillation (NVAF) but its cost-effectiveness remains understudied. This study evaluated the cost-effectiveness of LAAO for stroke prophylaxis in NVAF. METHODS: A Markov decision analytic model was used to compare the cost-effectiveness of LAAO with 7 pharmacological strategies: aspirin alone, clopidogrel plus aspirin, warfarin, dabigatran 110 mg, dabigatran 150 mg, apixaban, and rivaroxaban...
2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27555569/primary-and-key-secondary-results-from-the-rocket-af-trial-and-their-implications-on-clinical-practice
#10
Rohan Shah, Manesh R Patel
BACKGROUND: The safety and efficacy of the oral anticoagulant rivaroxaban were studied in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial). A number of subanalyses of the ROCKET AF trial have subsequently analyzed the use of rivaroxaban in special patient populations. METHODS: The outcomes of the ROCKET AF trial were reviewed. The use of rivaroxaban in higher risk populations, as determined by the presence of co-morbidities included in the CHADS2 criteria, was analyzed...
August 23, 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27550973/correction-to-on-treatment-outcomes-in-patients-with-worsening-renal-function-with-rivaroxaban-compared-with-warfarin-insights-from-rocket-af
#11
(no author information available yet)
No abstract text is available yet for this article.
August 23, 2016: Circulation
https://www.readbyqxmd.com/read/27539689/use-of-dual-antiplatelet-therapy-and-patient-outcomes-in-those-undergoing-percutaneous-coronary-intervention-the-rocket-af-trial
#12
Matthew W Sherwood, Derek D Cyr, W Schuyler Jones, Richard C Becker, Scott D Berkowitz, Jeffrey B Washam, Günter Breithardt, Keith A A Fox, Jonathan L Halperin, Graeme J Hankey, Daniel E Singer, Jonathan P Piccini, Christopher C Nessel, Kenneth W Mahaffey, Manesh R Patel
OBJECTIVES: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). BACKGROUND: The frequency, patterns, and outcomes when adding DAPT to non-vitamin K antagonist oral anticoagulants in the setting of PCI in patients with AF are largely unknown...
August 22, 2016: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27502854/blood-pressure-control-and-stroke-or-bleeding-risk-in-anticoagulated-patients-with-atrial-fibrillation-results-from-the-rocket-af-trial
#13
Sreekanth Vemulapalli, Anne S Hellkamp, W Schuyler Jones, Jonathan P Piccini, Kenneth W Mahaffey, Richard C Becker, Graeme J Hankey, Scott D Berkowitz, Christopher C Nessel, Günter Breithardt, Daniel E Singer, Keith A A Fox, Manesh R Patel
BACKGROUND: We conducted a retrospective analysis examining the association between systolic blood pressure (SBP) or hypertension bracket and stroke risk in patients with atrial fibrillation (AF). METHODS: The study included 14,256 anticoagulated patients in the ROCKET AF trial. Cox proportional hazards models were used to compare the risk of adverse outcomes by European Society of Cardiology hypertension bracket and screening SBP. RESULTS: In total, 90...
August 2016: American Heart Journal
https://www.readbyqxmd.com/read/27433845/point-of-care-warfarin-monitoring-in-the-rocket-af-trial
#14
LETTER
J Robert Powell
No abstract text is available yet for this article.
July 28, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27433844/point-of-care-warfarin-monitoring-in-the-rocket-af-trial
#15
COMMENT
Manesh R Patel, Anne S Hellkamp, Keith A A Fox
No abstract text is available yet for this article.
July 28, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27403287/controversy-surrounding-rocket-af-a-call-for-transparency-but-should-we-be-changing-practice
#16
Jason D Matos, Peter J Zimetbaum
No abstract text is available yet for this article.
May 2016: Arrhythmia & Electrophysiology Review
https://www.readbyqxmd.com/read/27358435/on-treatment-outcomes-in-patients-with-worsening-renal-function-with-rivaroxaban-compared-with-warfarin-insights-from-rocket-af
#17
Christopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, Samuel M Lindner, Jonathan P Piccini, Richard C Becker, Scott D Berkowitz, Günter Breithardt, Keith A A Fox, Kenneth W Mahaffey, Christopher C Nessel, Daniel E Singer, Manesh R Patel
BACKGROUND: Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin...
July 5, 2016: Circulation
https://www.readbyqxmd.com/read/27346176/bivariate-evaluation-of-thromboembolism-and-bleeding-in-clinical-trials-of-anticoagulants-in-patients-with-atrial-fibrillation
#18
John M Kittelson, Philippe Gabriel Steg, Jonathan L Halperin, Neil A Goldenberg, Sam Schulman, Alex C Spyropoulos, Craig M Kessler, Alexander G G Turpie, Neal R Cutler, William R Hiatt
Clinical trials of antithrombotic therapy require a cohesive assessment of benefit and risk. A new graphical method to represent the bivariate relation of benefit and risk in trials of antithrombotic drugs is described and illustrated using published data from the four major registration clinical trials of non-vitamin K oral anticoagulants (NOACs) totalling 71,683 patients for prevention of thromboembolic events (TE) in patients with atrial fibrillation (RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE-AF TIMI48). A curve representing a null hypothesis defines a region of benefit on a two-dimensional plane...
August 30, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27262782/efficacy-and-safety-of-non-vitamin-k-antagonist-oral-anticoagulants-after-cardioversion-for-nonvalvular-atrial-fibrillation
#19
Giulia Renda, Marco Zimarino, Fabrizio Ricci, Jonathan P Piccini, Michael D Ezekowitz, Manesh R Patel, Riccardo Cappato, Robert P Giugliano, Raffaele De Caterina
BACKGROUND: Non-vitamin K oral anticoagulants (NOACs) are proven alternatives to vitamin K antagonists (VKAs) for the prevention of thromboembolism in patients with nonvalvular atrial fibrillation. However, there are few data on the efficacy and safety of NOAC therapy after cardioversion, where the risk of thromboembolic events is heightened. METHODS: We performed a random-effects meta-analysis of patients who underwent both electrical and pharmacologic cardioversion for atrial fibrillation in the RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48, and X-VeRT trials...
October 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27174904/hospitalizations-in-patients-with-atrial-fibrillation-an-analysis-from-rocket-af
#20
Adam D DeVore, Anne S Hellkamp, Richard C Becker, Scott D Berkowitz, Guenter Breithardt, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Kenneth W Mahaffey, Christopher C Nessel, Daniel E Singer, Keith A A Fox, Manesh R Patel, Jonathan P Piccini
AIMS: The high costs associated with treatment for atrial fibrillation (AF) are primarily due to hospital care, but there are limited data to understand the reasons for and predictors of hospitalization in patients with AF. METHODS AND RESULTS: The ROCKET AF trial compared rivaroxaban with warfarin for stroke prophylaxis in AF. We described the frequency of and reasons for hospitalization during study follow-up and utilized Cox proportional hazards models to assess for baseline characteristics associated with all-cause hospitalization...
August 2016: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
keyword
keyword
108453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"